Cardiomyopathy and Other Myocardial Diseases: How Heart Muscle Conditions Are Treated

The echo report is a single page, but one line stops everyone at the kitchen table: ejection fraction 35 percent. A number that meant nothing last week now sits next to a word nobody can pronounce. Cardiomyopathy. The cardiologist has already said something reassuring about medicines, and something less reassuring about a follow-up scan in a few months, and both sentences have blurred together on the drive home.

Part of the confusion is that there is no single treatment to explain. The types of cardiomyopathy treatment differ because the diseases differ: a heart that has stretched and weakened needs the opposite approach from a heart whose wall has grown thick and stiff, and a heart infiltrated by an abnormal protein needs something different again.

This explainer walks through what each of those approaches is actually doing inside the chest, who tends to be offered what, and which of the questions people type into a search bar at midnight have honest answers.

What is cardiomyopathy, and why does the type steer the treatment?

Cardiomyopathy means disease of the heart muscle itself, rather than of the valves that open and close inside it or the coronary arteries that feed it. The broader phrase myocardial disease covers the same territory and also takes in inflammation of the muscle, called myocarditis, and conditions where something abnormal builds up inside the muscle wall.

Cardiologists sort the classic forms by shape and behavior. In dilated cardiomyopathy the main pumping chamber, the left ventricle, stretches and weakens. In hypertrophic cardiomyopathy the wall thickens without a good reason such as high blood pressure; the Mayo Clinic notes it affects roughly 1 in 500 people and is often inherited. Restrictive cardiomyopathy leaves the walls stiff so the chamber cannot fill properly. Arrhythmogenic cardiomyopathy replaces patches of muscle with scar and fat, which sets the stage for dangerous rhythms. Around these sit named causes: peripartum cardiomyopathy in late pregnancy or the months after birth, stress-induced (takotsubo) cardiomyopathy, alcohol-related and chemotherapy-related muscle damage, and infiltrative diseases such as amyloidosis and sarcoidosis.

One measurement runs through nearly every conversation. Ejection fraction is the share of blood the left ventricle pushes out with each beat; the American Heart Association gives a normal range of about 55 to 70 percent. A low number points toward a weak, dilated heart. A normal or even high number with thick walls points the other way.

That is why the type matters so much. A stretched heart benefits from medicines that lower its workload and pressure. A thick, stiff heart can be harmed by the same medicines, because it depends on adequate filling pressure and a slow, steady rhythm to work at all. Two people with identical breathlessness may leave the clinic with prescriptions built on opposite logic, and both can be correct.

How cardiomyopathy treatment actually works: four jobs at once

Whatever the type, treatment is trying to do four things, and it helps to know which job each part of the plan is doing.

The first job is relieving congestion. When a heart cannot move blood forward efficiently, fluid backs up into the lungs and legs. Diuretics, sometimes called water tablets, prompt the kidneys to release more salt and water, which eases breathlessness and swelling within days. They treat the symptom, not the disease, so they are almost never used alone.

The second job is protecting the muscle from its own stress response. A struggling heart triggers a flood of adrenaline and kidney hormones that raise blood pressure and heart rate. That rescue reflex helps for hours and harms for years, driving further stretching and scarring. Several medicine classes exist to blunt that cascade, and they form the backbone of dilated cardiomyopathy care.

The third job is preventing dangerous rhythms and strokes. Diseased muscle conducts electricity unevenly, which raises the risk of ventricular arrhythmias and of atrial fibrillation, an irregular rhythm in the upper chambers that can let clots form. Rhythm-control medicines, blood thinners, implanted defibrillators and catheter procedures all belong here.

The fourth job is treating the cause when one can be found. Removing alcohol, correcting a thyroid disorder, controlling a racing heart rate, suppressing inflammation or targeting an abnormal protein can change the trajectory in a way no symptom medicine can.

Layered on top are the unglamorous parts: limiting sodium, moving daily, treating sleep apnea, managing blood pressure and diabetes. Guidelines from the NHS and the American Heart Association treat these as therapy, not decoration. The care team decides how the layers stack, and reviews the stack as the heart responds or does not.

Dilated cardiomyopathy treatment: what each medicine is doing

Dilated cardiomyopathy is the form most people mean when they say heart failure with a weak pump, and its medicines are the ones people usually have in mind when they ask about the most common treatment. Four classes are typically introduced, one after another, as blood pressure and kidney function allow.

Renin-angiotensin blockers, including ACE inhibitors, angiotensin receptor blockers and the newer combination known as an ARNI, relax blood vessels and switch off a hormone pathway that drives the heart to stretch further. Beta blockers dampen adrenaline, slowing the heart and giving weakened muscle longer to fill and rest between beats; they can make people feel more tired for the first few weeks before the benefit appears. Mineralocorticoid receptor antagonists block aldosterone, a hormone that encourages scarring and fluid retention. SGLT2 inhibitors were designed for diabetes and turned out to reduce heart failure hospital admissions in large trials; the mechanism is still being worked out and seems to involve the kidney and the heart’s fuel use rather than blood sugar alone.

None of these medicines makes a person feel dramatically better on day one. Their purpose is remodeling, the slow reversal of stretching and thinning, and the Mayo Clinic describes benefit accumulating over months rather than days. Diuretics run alongside for comfort, adjusted to weight and swelling.

Where atrial fibrillation is present, an anticoagulant to reduce stroke risk often joins the list. Where a cause is found, treating it comes first: alcohol cessation, thyroid correction, stopping a culprit drug where the prescriber agrees an alternative exists.

Which medicines, in what order and how fast, belongs to the prescribing cardiologist, who is balancing blood pressure, kidney numbers and how a person is coping. The pattern is universal; the details never are.

Hypertrophic cardiomyopathy treatment options: relaxing a muscle that works too hard

Hypertrophic cardiomyopathy is the mirror image of the dilated form. The muscle is not weak; it is thick, overactive and slow to relax. In many people the thickened wall between the two ventricles, the septum, bulges into the outflow path so that blood has to squeeze past it on the way to the aorta. Cardiologists call this obstruction, and the mitral valve is often dragged into the jet, leaking backward.

Medicines therefore aim to calm rather than support. Beta blockers and certain calcium channel blockers slow the heart, lengthen filling time and reduce how forcefully the septum contracts, which can widen that narrow exit. Disopyramide, an older antiarrhythmic, is sometimes added for the same reason. Cardiac myosin inhibitors are the newest class: they act directly on myosin, the motor protein inside muscle cells, to reduce excessive contraction. Because they can lower pumping strength too far, they require regular echocardiograms while being used.

When symptoms persist despite medicines and obstruction is significant, two septal reduction procedures exist. Surgical myectomy removes a sliver of the thickened septum through open heart surgery. Alcohol septal ablation threads a catheter into the small artery feeding that muscle and injects alcohol to shrink it. Each has its own risks, including the need for a pacemaker afterward, and the choice depends on anatomy, age, other conditions and local expertise.

Sudden cardiac death is the fear that shadows this diagnosis, and it is addressed by risk scoring: wall thickness, fainting history, family history, scar on MRI and rhythm recordings. People judged to be at higher risk are offered an implantable defibrillator.

Two practical points follow the physiology. A thick heart tolerates dehydration poorly, so fluid intake in heat and illness matters. Because the condition is often inherited, first-degree relatives are usually offered screening.

Restrictive, amyloid and inflammatory heart muscle disease: treating the cause first

Restrictive cardiomyopathy is the least common classic type and the one where the phrase treat the cause carries the most weight. The walls are not necessarily thick or thin; they are stiff, so the ventricle cannot relax enough to fill. Pumping strength on the echo may look normal while the person is profoundly breathless.

The causes are a list of things that infiltrate or scar muscle. Cardiac amyloidosis deposits misfolded protein between muscle fibers. There are two main forms: AL amyloidosis, driven by abnormal plasma cells and treated by hematologists with chemotherapy-type regimens, and transthyretin (ATTR) amyloidosis, where a liver-made protein misfolds, sometimes because of an inherited gene and sometimes simply with age. Newer medicines stabilize or silence transthyretin, which is why cardiologists now test for amyloid far more readily than a generation ago. Cardiac sarcoidosis forms inflammatory clusters called granulomas and is treated with immunosuppression. Iron overload from repeated transfusions or hereditary hemochromatosis is treated by removing iron. Scarring after chest radiation is managed rather than reversed.

Standard heart failure medicines are used cautiously here. A stiff heart depends on filling pressure, so diuretics and blood pressure lowering drugs can tip a person into dizziness and low output. In amyloid, several of the usual classes are poorly tolerated and their benefit is unproven; the Cleveland Clinic and the American Heart Association both describe management as supportive and cause-directed.

Myocarditis, inflammation of the muscle usually triggered by a viral infection, sits in the same family. Most cases are treated with rest, avoidance of strenuous exercise while the heart heals, and heart failure medicines if pumping is reduced. Specific immune therapies are reserved for identified inflammatory subtypes confirmed by MRI or biopsy. Follow-up imaging determines when normal activity can resume, and that call belongs to the treating team.

Devices, surgery and transplant: when medicines are not enough

Arrhythmogenic cardiomyopathy shows why devices matter. Here the disease is less about pumping and more about electricity: as scar and fat replace healthy muscle, usually in the right ventricle, the heart becomes prone to sustained fast rhythms. Intense endurance exercise appears to accelerate the process, so activity restriction is part of treatment, and an implantable cardioverter defibrillator is frequently recommended.

An ICD is a small generator placed under the skin with a lead to the heart; it watches every beat and delivers a shock if it detects a life-threatening rhythm. It does not make the heart stronger and it does not prevent the arrhythmia from starting, which surprises many people. Risks include infection, lead fracture and shocks delivered for rhythms that were not dangerous.

Cardiac resynchronization therapy is a pacemaker with an extra lead that coordinates the two ventricles when the ECG shows a conduction delay making them beat out of step. In the right candidates it can improve symptoms and pumping; in people without that delay it offers little. Catheter ablation uses heat or cold to destroy small areas of tissue causing atrial fibrillation or ventricular tachycardia.

At the far end of the pathway sit mechanical support and transplant. A left ventricular assist device is a pump connected to the left ventricle that takes over most of its work, powered through a cable exiting the abdomen. It is used while waiting for a transplant or as long-term therapy when transplant is not an option; bleeding, stroke, cable-site infection and pump problems are the recognized hazards. Heart transplant replaces the organ entirely and brings lifelong immunosuppression and a limited donor supply.

Each step is a judgment about symptoms, risk and goals. Advanced heart failure teams make those judgments together with the person living in the body in question.

Types of cardiomyopathy treatment at a glance

The table below compresses the previous sections. It is a map, not a menu: a person may have features of more than one row, and every entry is conditional on what the individual heart shows on imaging and rhythm monitoring.

Type	What is wrong with the muscle	Usual medicine strategy	Procedures sometimes considered
Dilated	Stretched, thin, weak pump; low ejection fraction	Heart failure classes that unload the heart and block stress hormones; diuretics for fluid; anticoagulant if atrial fibrillation	ICD, resynchronization pacing, assist device, transplant
Hypertrophic	Thick, overactive wall; often obstructs outflow	Beta blockers or calcium channel blockers to slow and relax; cardiac myosin inhibitors in obstructive disease	Septal myectomy, alcohol septal ablation, ICD if high sudden-death risk
Restrictive and infiltrative	Stiff walls that cannot fill; deposits or scar	Treat the cause: amyloid-directed therapy, immunosuppression for sarcoid, iron removal; cautious diuretics	Pacemaker for conduction block; transplant in selected cases
Arrhythmogenic	Muscle replaced by scar and fat; unstable rhythms	Rhythm-control medicines; exercise restriction	ICD, catheter ablation
Peripartum, stress-induced, toxin-related	Acute weakening with a trigger	Standard heart failure medicines adjusted for pregnancy or breastfeeding; remove the trigger	Temporary support if severe; often none as the heart recovers

Two patterns stand out. First, the dilated and hypertrophic rows point in opposite directions, which is why borrowing a relative’s medicine or a forum’s advice can be actively dangerous. Second, the procedures column is dominated by rhythm devices rather than operations on the muscle itself; for most people the muscle is treated chemically and the electricity is treated mechanically. The MedlinePlus overview of cardiomyopathy describes the same division.

Who is treated straight away, and who is asked to wait and watch?

Not everyone with a cardiomyopathy diagnosis leaves with a prescription, and being told to wait can feel worse than being told to start. It helps to understand what tips the scales.

Treatment usually begins promptly when there are symptoms such as breathlessness, swelling or fainting; when ejection fraction is clearly reduced; when atrial fibrillation or ventricular arrhythmias have been recorded; when a hypertrophic heart shows significant obstruction with symptoms; or when risk scores for sudden death are high. A cause that can be removed, such as heavy alcohol use or a runaway heart rate, is addressed at the first visit regardless of how mild things look.

Watchful monitoring is more common than people expect. Relatives who carry a disease-causing gene variant but have a normal heart on imaging, described as genotype positive and phenotype negative, are typically followed with periodic echocardiograms and ECGs rather than medicated, because no medicine has yet been proven to stop the disease appearing. Mild wall thickening in a young endurance athlete may represent athlete’s heart, a healthy adaptation, and is often re-scanned after a period of reduced training before any label is applied. Stress-induced cardiomyopathy frequently recovers on its own within weeks, so treatment is short and supportive. A borderline ejection fraction with no symptoms may be rechecked before lifelong therapy starts.

Waiting is an active decision with a schedule attached: a repeat scan, a rhythm monitor, a set of blood tests, and clear instructions about which symptoms should bring the appointment forward. The NHS cardiomyopathy guidance frames this as ongoing review rather than discharge.

Children follow a similar logic with extra caution, because growth changes heart measurements and because many pediatric cases have a metabolic or genetic cause worth hunting for before any long-term plan is set.

What the first weeks and months of treatment usually look like

The early phase of dilated cardiomyopathy treatment is deliberately unhurried. Medicines are introduced one class at a time and the prescriber increases each one stepwise at follow-up visits, watching blood pressure, heart rate, kidney function and potassium. Blood tests are common in the first weeks because some of these medicines shift kidney numbers before settling. People are often asked to weigh themselves each morning and record it, since a rapid gain usually means fluid rather than fat.

Feeling slightly worse before feeling better is a recognized pattern, particularly with beta blockers, which can bring tiredness and lightheadedness while the body adjusts. The Mayo Clinic describes the benefit of heart failure medicines building over months, and most cardiologists schedule a repeat echocardiogram after a stretch of optimized therapy to see how the ejection fraction has responded. That repeat scan often decides the next question: whether a defibrillator is now warranted, whether the plan is working well enough to continue as is, or whether a referral to an advanced heart failure service makes sense.

Hypertrophic cardiomyopathy follows a different rhythm. Medicine adjustments are judged mainly by symptoms and by the measured obstruction on echo, and anyone started on a myosin inhibitor has scans at set intervals to confirm pumping strength has not fallen too far.

After a septal myectomy or a device implant, recovery resembles that of other cardiac surgery or pacemaker procedures: a hospital stay, wound care, arm movement restrictions after a device lead, and a gradual return to activity guided by the surgical team. Cardiac rehabilitation, a supervised exercise and education program, is offered widely and the American Heart Association encourages it for heart failure generally.

None of these timelines is a promise. They describe the shape of the road, and the treating team sets the pace.

What is the newest treatment for cardiomyopathy, and how solid is the evidence?

The most-searched question about cardiomyopathy deserves a careful answer, because new and proven are not the same thing.

The clearest genuine advance is the cardiac myosin inhibitor class for obstructive hypertrophic cardiomyopathy. These medicines target the disease mechanism directly rather than just slowing the heart, and randomized trials in adults showed improvements in symptoms and obstruction. Trials in non-obstructive disease, where there is no narrowing to relieve, have been less convincing, and use requires echo monitoring because pumping strength can drop. This is a regulated prescription therapy decided by a cardiologist, not something to request by name.

For dilated cardiomyopathy the recent shift has been the arrival of SGLT2 inhibitors as a fourth pillar alongside the three older classes, supported by large trials showing fewer heart failure hospitalizations. The ARNI combination is somewhat older but is still described as new by many patients.

Transthyretin amyloid cardiomyopathy has moved from untreatable to treatable within a decade. Stabilizer medicines that hold the protein in its correct shape were the first to show benefit in a large trial; RNA-based silencers that reduce production have followed; and a single-dose gene-editing approach is in clinical trials but is not standard care.

Gene therapy for inherited hypertrophic and dilated cardiomyopathy, in which a working copy of a gene is delivered to heart cells, has reached early human studies. The honest summary is that it is promising, experimental and years from routine use. Anyone offered it outside a registered trial should be skeptical.

Newest also does not mean best for a given person. An older beta blocker may remain the right first step for many. The role of a good cardiologist is to match the mechanism of the medicine to the mechanism of the disease in front of them, and the research literature indexed in PubMed continues to shift that matching year by year.

What people often get wrong about cardiomyopathy

Cardiomyopathy is not a heart attack. A heart attack is a blocked artery starving a region of muscle; cardiomyopathy is a disease of the muscle itself, and many people with it have perfectly clear coronary arteries. The confusion matters because friends and relatives may offer heart attack advice, such as pushing hard on cholesterol, that misses the point.

A low ejection fraction is not a countdown. The number reflects the heart’s pumping strength at one moment. With treatment it can improve substantially in dilated cardiomyopathy, and people live full lives with numbers that sounded frightening at diagnosis. Equally, a normal ejection fraction does not mean a healthy heart; hypertrophic and restrictive disease can be severe with a textbook-perfect number.

Can cardiomyopathy be reversed? Sometimes, and the type decides it. Stress-induced, peripartum, alcohol-related and rhythm-induced forms often recover once the trigger is gone and the heart is supported, and some dilated hearts remodel back toward normal on medicines. Hypertrophic cardiomyopathy caused by a gene variant does not un-thicken; the goal there is control. Anyone promising reversal for every type is selling something.

Exercise is not universally banned. Older guidance leaned heavily on restriction, particularly for hypertrophic disease. Current thinking is individualized: many people are encouraged to stay active at moderate intensity after risk assessment, while a smaller group with arrhythmogenic disease or high-risk features are asked to avoid competitive or intense endurance sport. The decision is medical, not moral.

Supplements do not treat heart muscle disease. Coenzyme Q10, fish oil, hawthorn and taurine appear constantly in forums; none has guideline-level evidence for cardiomyopathy, and some interact with anticoagulants or rhythm medicines. The NIH Office of Dietary Supplements is a sober place to check any product before mentioning it to a pharmacist, which is the right order of operations.

Children get cardiomyopathy too, and it is not always inherited. Metabolic and infectious causes are more common in the very young, which is why pediatric work-ups tend to be broad.

What should you not do with cardiomyopathy?

The most dangerous thing to do is stop a prescribed medicine abruptly because the side effects are annoying or the symptoms have eased. Beta blockers in particular can cause a rebound surge in heart rate and blood pressure when stopped suddenly, and the protective medicines only protect while they are being taken. Side effects are real and worth reporting; the prescriber can adjust, substitute or slow down, but that conversation needs to happen before anything changes.

Heavy alcohol use is directly toxic to heart muscle and is itself a cause of dilated cardiomyopathy. For people whose disease is alcohol-related, abstinence is the treatment. For everyone else, the cardiology team will give a view on what, if anything, is reasonable.

Stimulants are a poor match for a diseased heart. Cocaine and amphetamines can trigger lethal rhythms. Large quantities of caffeine and energy drinks raise heart rate and are worth discussing. Over-the-counter decongestants containing pseudoephedrine or phenylephrine tighten blood vessels and push up blood pressure; a pharmacist can suggest alternatives.

Common anti-inflammatory painkillers such as ibuprofen and naproxen cause the kidneys to retain salt and water, which can undo the work of a diuretic and push someone into a hospital admission. Ask before using them for more than the occasional dose.

People with hypertrophic disease should avoid dehydration, prolonged hot tubs and saunas, and sudden bursts of maximal effort without clearance, because a thick heart with low filling can lose output quickly.

Do not ignore weight. A gain of a few pounds over a couple of days almost always means fluid and is the earliest warning most people get.

Do not plan a pregnancy without involving the cardiology team first. Pregnancy roughly doubles the heart’s workload, several heart failure medicines are unsafe for a developing baby, and a planned, supervised pregnancy has a very different risk profile from an unplanned one.

Smoking damages the vessels feeding an already stressed muscle. Stopping is one of the few interventions that helps every type of cardiomyopathy equally.

Questions to ask your care team

Cardiology appointments are short and the vocabulary is dense. Writing questions down beforehand changes the balance of the conversation. These are the ones that tend to unlock the most useful answers.

• Which type of cardiomyopathy do I have, and how confident are you in that classification?
• Have you identified a cause, and is there anything about it that can be removed or treated directly?
• What is my ejection fraction, and what other measurement matters most for my type?
• Which of my medicines is for comfort and which is for protecting the heart over time?
• What side effects should I expect in the first weeks, and which ones mean I should call rather than wait?
• When is my next scan, and what result would change the plan?
• Have you assessed my risk of dangerous rhythms, and where do I sit on that scale?
• Would a defibrillator or pacing device be considered for me now or later, and what would tip that decision?
• Is genetic testing appropriate, and should my parents, siblings or children be screened?
• What kind and intensity of exercise is safe for me, and is cardiac rehabilitation available?
• Are there medicines, supplements or over-the-counter products I should avoid?
• If I am planning a pregnancy or travel, what needs to happen first?
• Am I a candidate for any clinical trial, and how would I find out?
• Who do I contact between appointments, and how quickly can I expect a response?

A good team welcomes this list. If an answer is uncertain, the honest reply is often that a repeat scan or a specialist opinion is needed, and hearing that is more useful than a confident guess. Bring someone with you when you can; two sets of ears catch more, and the person who drives you home is often the one who remembers the details about weighing scales and fluid.

When to call your doctor

Living with heart muscle disease means learning the difference between a bad day and a warning. The Mayo Clinic and the NHS list the same core signals, and they divide neatly into two tiers.

Call emergency services, not the clinic, for chest pain or pressure that lasts more than a few minutes or comes with sweating and nausea; fainting or a near-faint, especially during exertion; sudden severe breathlessness or breathlessness at rest that is getting worse by the minute; a very fast heartbeat that will not settle and comes with dizziness; a shock from an implanted defibrillator followed by feeling unwell, or more than one shock in a day; or sudden weakness, facial drooping or trouble speaking, which may be a stroke.

Contact your cardiology team or primary care doctor the same day for a weight gain of a few pounds over two or three days, new or worsening swelling of the ankles, legs or abdomen, needing extra pillows or waking breathless in the night, a new persistent cough or wheeze, palpitations that are new or more frequent, dizziness when standing that has appeared since a medicine change, a fever or flu-like illness that leaves you unable to keep fluids down, or any new medicine another doctor wants you to start.

Do not wait for the scheduled appointment to report side effects that are making it hard to keep taking a medicine. The team would rather adjust the plan than discover at the next visit that it was quietly abandoned.

Children with cardiomyopathy show distress differently: feeding poorly, sweating during feeds, breathing fast, or simply being unusually floppy or tired. Parents who notice a change should call their pediatric cardiology team the same day and trust their instinct that something is off.

Every decision described in this article, from the first prescription to the last device, belongs to the people treating you. Their job is to weigh your heart and your life together; yours is to give them the information to do it well.

Frequently asked questions

What is the most common treatment for cardiomyopathy?

For most people the most common treatment is a combination of heart failure medicines, because dilated cardiomyopathy is the most frequent form. These include renin-angiotensin blockers, beta blockers, mineralocorticoid receptor antagonists and SGLT2 inhibitors, with diuretics for fluid symptoms. Lifestyle measures such as sodium restriction, activity and alcohol limits run alongside. Which classes are used, and in what order, is decided by the prescribing cardiologist based on the type of cardiomyopathy and the individual’s blood pressure and kidney function.

What is the most serious type of cardiomyopathy?

There is no single most serious type; severity depends more on how advanced the disease is and whether dangerous rhythms are present than on the label. Restrictive cardiomyopathy and cardiac amyloidosis have historically been the hardest to treat because standard medicines work poorly on stiff hearts, although amyloid-directed therapies have changed that picture. Arrhythmogenic cardiomyopathy carries a notable rhythm risk in young people. Any type can be mild or life-threatening, which is why individual risk assessment matters more than the category.

Can cardiomyopathy be reversed?

Some types can improve substantially, and a few can return to near-normal function. Stress-induced (takotsubo), peripartum, alcohol-related and rhythm-induced cardiomyopathy often recover once the trigger is removed and the heart is supported, and dilated hearts can remodel back toward normal on optimized medicines over months. Inherited hypertrophic cardiomyopathy does not un-thicken and is managed rather than reversed. Recovery is never guaranteed, and the treating team judges it with repeat imaging rather than assumptions.

What is the newest treatment for cardiomyopathy?

The most established recent advance is the cardiac myosin inhibitor class for obstructive hypertrophic cardiomyopathy, which targets the overactive muscle protein directly. For dilated disease, SGLT2 inhibitors have joined the standard medicine set. Transthyretin amyloid cardiomyopathy now has stabilizer and gene-silencing therapies, with gene editing in trials. Gene therapy for inherited forms is in early human studies and is not standard care. Newer is not automatically better for a given person; suitability is a specialist decision.

Is cardiomyopathy the same as heart failure?

No, though they overlap. Cardiomyopathy is a disease of the heart muscle; heart failure is the clinical state in which the heart cannot meet the body’s needs, whatever the cause. Many people with cardiomyopathy develop heart failure symptoms, and cardiomyopathy is a leading cause of heart failure, but some people with cardiomyopathy have no symptoms, and heart failure can also result from valve disease or coronary artery disease without any primary muscle disorder.

Do all people with cardiomyopathy need a defibrillator?

No. An implantable cardioverter defibrillator is offered when the assessed risk of a life-threatening rhythm is high enough to justify the device’s own risks. That assessment uses ejection fraction, symptoms, fainting history, family history, wall thickness, scar on MRI and recorded arrhythmias, and it differs by type. Many people with well-controlled cardiomyopathy never need one, and in dilated disease the decision is often deferred until medicines have had months to improve pumping strength.

Can I exercise if I have cardiomyopathy?

Most people can and are encouraged to stay active at a moderate level, but the type and intensity should be agreed with the cardiology team after risk assessment. Regular walking, cycling and supervised cardiac rehabilitation are widely recommended for heart failure. People with arrhythmogenic cardiomyopathy, high-risk hypertrophic features or recent myocarditis are usually asked to avoid competitive or intense endurance sport, at least until follow-up imaging. Blanket bans on exercise are no longer standard advice.

Is cardiomyopathy hereditary, and should my children be tested?

Many forms are inherited, especially hypertrophic, arrhythmogenic and a share of dilated cardiomyopathy, so first-degree relatives are commonly offered screening with an ECG and echocardiogram. If a disease-causing gene variant is found in the affected person, relatives can be offered genetic testing to learn whether they carry it. Children who carry a variant but have a normal heart are usually monitored periodically rather than treated. A genetics counselor can explain the options for a specific family.

How is cardiomyopathy diagnosed?

Diagnosis starts with a physical examination, an ECG to record electrical activity, and an echocardiogram, which is an ultrasound that measures wall thickness, chamber size and ejection fraction. Cardiac MRI adds detail about scar and inflammation, blood tests check for strain markers and possible causes, and a portable rhythm monitor looks for arrhythmias. Genetic testing, nuclear scans for amyloid or, rarely, a small biopsy of heart muscle are used when the picture is unclear.

Can I get pregnant if I have cardiomyopathy?

Many people with stable cardiomyopathy do carry pregnancies safely, but planning ahead is essential. Pregnancy sharply increases the heart’s workload, several heart failure medicines are unsafe for a developing baby and need to be reviewed by the prescriber before conception, and anyone with a history of peripartum cardiomyopathy carries a recurrence risk. Pre-pregnancy counseling with a cardiologist and an obstetrician experienced in heart disease lets the team assess risk and arrange monitoring throughout.

References

• NHS: Cardiomyopathy
• MedlinePlus: Cardiomyopathy

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.